RAPT Therapeutics, Inc. (NASDAQ:RAPT) CFO Buys $52,650.00 in Stock

RAPT Therapeutics, Inc. (NASDAQ:RAPT – Get Rating) CFO Rodney Kb Young acquired 5,000 shares of the stock in a transaction on Tuesday, May 10th. The stock was bought at an average cost of $10.53 per share, for a total transaction of $52,650.00. Following the transaction, the chief financial officer now owns 10,084 shares of the company’s stock, valued at approximately $106,184.52. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link.

Shares of NASDAQ RAPT opened at $12.16 on Friday. RAPT Therapeutics, Inc. has a 1 year low of $9.85 and a 1 year high of $43.26. The firm has a 50-day moving average of $19.81 and a 200 day moving average of $26.19.

RAPT Therapeutics (NASDAQ:RAPT – Get Rating) last issued its earnings results on Wednesday, May 11th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.01). RAPT Therapeutics had a negative return on equity of 39.69% and a negative net margin of 1,814.95%. As a group, research analysts forecast that RAPT Therapeutics, Inc. will post -3.04 earnings per share for the current fiscal year.

A number of institutional investors have recently modified their holdings of the business. Perceptive Advisors LLC raised its holdings in RAPT Therapeutics by 0.7% in the fourth quarter. Perceptive Advisors LLC now owns 2,927,565 shares of the company’s stock worth $107,529,000 after buying an additional 20,000 shares during the last quarter. BlackRock Inc. grew its stake in shares of RAPT Therapeutics by 18.0% in the third quarter. BlackRock Inc. now owns 1,898,821 shares of the company’s stock worth $58,957,000 after acquiring an additional 290,159 shares during the period. Wellington Management Group LLP grew its stake in shares of RAPT Therapeutics by 14.1% in the third quarter. Wellington Management Group LLP now owns 1,507,203 shares of the company’s stock worth $46,798,000 after acquiring an additional 186,068 shares during the period. State Street Corp grew its stake in shares of RAPT Therapeutics by 260.7% in the fourth quarter. State Street Corp now owns 1,243,787 shares of the company’s stock worth $45,684,000 after acquiring an additional 898,950 shares during the period. Finally, Kingdon Capital Management L.L.C. grew its stake in shares of RAPT Therapeutics by 18.3% in the third quarter. Kingdon Capital Management L.L.C. now owns 1,148,321 shares of the company’s stock worth $35,655,000 after acquiring an additional 177,500 shares during the period. 95.22% of the stock is owned by institutional investors and hedge funds.

Several brokerages have commented on RAPT. Zacks Investment Research lowered shares of RAPT Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, January 20th. Piper Sandler lowered their price objective on shares of RAPT Therapeutics from $52.00 to $30.00 in a research report on Thursday. Wells Fargo & Company lowered their price objective on shares of RAPT Therapeutics from $65.00 to $55.00 and set an “overweight” rating on the stock in a research report on Friday, March 11th. HC Wainwright reiterated a “buy” rating and issued a $56.00 target price on shares of RAPT Therapeutics in a research note on Monday, March 14th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of RAPT Therapeutics in a research note on Friday, April 1st. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $52.25.

RAPT Therapeutics Company Profile (Get Rating)

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

Featured Articles